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BACKGROUND
Whole-exome sequencing has transformed gene discovery and diagnosis in rare 
diseases. Translation into disease-modifying treatments is challenging, particu-
larly for intellectual developmental disorder. However, the exception is inborn 
errors of metabolism, since many of these disorders are responsive to therapy that 
targets pathophysiological features at the molecular or cellular level.
METHODS
To uncover the genetic basis of potentially treatable inborn errors of metabolism, 
we combined deep clinical phenotyping (the comprehensive characterization of the 
discrete components of a patient’s clinical and biochemical phenotype) with 
whole-exome sequencing analysis through a semiautomated bioinformatics pipe-
line in consecutively enrolled patients with intellectual developmental disorder and 
unexplained metabolic phenotypes.
RESULTS
We performed whole-exome sequencing on samples obtained from 47 probands. 
Of these patients, 6 were excluded, including 1 who withdrew from the study. The 
remaining 41 probands had been born to predominantly nonconsanguineous par-
ents of European descent. In 37 probands, we identified variants in 2 genes newly 
implicated in disease, 9 candidate genes, 22 known genes with newly identified 
phenotypes, and 9 genes with expected phenotypes; in most of the genes, the vari-
ants were classified as either pathogenic or probably pathogenic. Complex pheno-
types of patients in five families were explained by coexisting monogenic condi-
tions. We obtained a diagnosis in 28 of 41 probands (68%) who were evaluated. 
A test of a targeted intervention was performed in 18 patients (44%).
CONCLUSIONS
Deep phenotyping and whole-exome sequencing in 41 probands with intellectual 
developmental disorder and unexplained metabolic abnormalities led to a diagno-
sis in 68%, the identification of 11 candidate genes newly implicated in neuro-
metabolic disease, and a change in treatment beyond genetic counseling in 44%. 
(Funded by BC Children’s Hospital Foundation and others.)
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Next-generation sequencing has revolutionized the discovery of genes in which variants cause rare mendelian 
diseases.1 A diagnostic yield of 16% (with most 
variants classified as de novo mutations) has 
been documented for whole‐exome sequencing 
among patients with unexplained intellectual 
developmental disorder,2,3 a condition that affects 
an estimated 3% of the population worldwide.4 
Along with coexisting illnesses that include epi-
lepsy, psychiatric or behavioral disturbances, 
movement disorders, sensory deficits, and other 
organ dysfunction, intellectual developmental dis-
order poses a substantial emotional, functional, 
and economic burden.5 Copy-number variants, 
methylation abnormalities, and single-gene de-
fects are known to cause intellectual develop-
mental disorder.2,3,6,7
Diagnosis is essential for accurate genetic 
counseling, informed decision making by fami-
lies and physicians, and access to appropriate 
medical support and services in the community 
but does not often translate into disease-modify-
ing treatments. The exception is inborn errors of 
metabolism, the largest group of genetic intel-
lectual developmental disorders that are amena-
ble to causal therapy — in other words, interven-
tions that directly target pathogenesis at the 
cellular and molecular level.8 For example, the 
discovery that pyridoxine-dependent epilepsy is 
caused by variants in ALDH7A1, which encodes 
an enzyme that catabolizes lysine, led to the 
implementation of a lysine-restricted diet and ar-
ginine supplementation, which improved neuro-
developmental outcomes.9 Approximately 90 treat-
able inborn errors of metabolism are known to 
cause intellectual developmental disorder,8,10,11 
and it seems likely that more such neurometa-
bolic disorders remain to be discovered. We 
therefore sequenced the exomes of consecutive 
patients with intellectual developmental disorder 
that had an unexplained metabolic phenotype 
and then used a semiautomated bioinformatics 
pipeline and a multidisciplinary approach to 
identify causal variants.
Me thods
Patients
Patients of all ages were consecutively enrolled if 
they had confirmed or potential intellectual de-
velopmental disorder (i.e., the presence of toxic 
metabolites that are known to cause brain dam-
age in the neonatal period) along with a meta-
bolic phenotype of unknown cause after com-
prehensive clinical phenotyping with extensive 
previous metabolic or genetic testing. A meta-
bolic phenotype was defined as one or more of 
the following: a pattern of abnormal metabolites 
in urine, blood, or cerebrospinal fluid; abnormal 
results on functional studies at a biochemical or 
cellular level (e.g., a deficiency in the mitochon-
drial-respiratory-chain complex); or abnormali-
ties on clinical history (e.g., developmental or 
cognitive regression), physical examination (e.g., 
organomegaly), neuroimaging or physiological 
analysis (e.g., leukodystrophy), or pathological 
analysis (e.g., storage vacuoles) suggestive of a 
neurometabolic disorder.
The study was approved by the ethics commit-
tee of the Faculty of Medicine at the University 
of British Columbia. Each patient or designated 
guardian provided written informed consent for 
participation in the study and publication of the 
results. During the informed-consent process, 
investigators explained the risks and benefits of 
research-based whole-exome sequencing analy-
sis to patients and their families, and an option 
for disclosure of medically actionable incidental 
findings was provided.
Sequencing and Bioinformatics Analysis
We isolated genomic DNA, using standard tech-
niques, from either peripheral blood or saliva ob-
tained from the proband and from both parents 
and all affected and unaffected siblings (if avail-
able). We performed whole-exome sequencing 
analysis on samples obtained from the probands, 
the parents, and any affected siblings using ei-
ther the SureSelect targeted capture kit (Agilent) 
on the Illumina HiSeq 2000 sequencer or the Ion 
AmpliSeq Exome Kit and Ion Proton System 
(ThermoFisher).
We developed and applied a semiautomated 
gene-discovery pipeline, which involves manual 
inspection of data quality and collaborative inter-
actions between clinicians and bioinformaticians 
(Fig. 1). (Details are provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org.) After the completion of 
whole-exome sequencing, we provided a clinician-
referral form containing data on phenotype, fam-
ily history with pedigree, ancestry, and previous 
results of diagnostic testing for variant interpre-
tation. We classified the pathogenicity of the 
variants according to recent standards and guide-
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Figure 1. Flow Chart Showing Gene-Discovery Approach with the Use of Collaborative Phenomics and Semiautomated 
Genomics.
This research process of uncovering the genetic basis of potentially treatable neurometabolic conditions in patients 
with an intellectual developmental disorder (IDD) involves a combination of deep clinical phenotyping (the compre-
hensive characterization of the discrete components of a patient’s clinical and biochemical phenotype), whole-exome 
sequencing analysis, team interpretation, validation, and translation to the clinical setting. Whole-exome sequencing 
analysis is performed on DNA samples obtained from the proband and on available samples from parents and any 
affected siblings. The semiautomated gene-discovery pipeline involves manual inspection of data quality and collab-
orative interactions among clinicians, laboratory scientists, and bioinformaticians for interpretation, candidate-gene 
selection, and subsequent experimental and clinical validations. The benefits of a diagnosis for patients and their 
families are shown; in some cases, the diagnosis enables a targeted treatment strategy. Details are provided in the 
Supplementary Appendix.
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lines of the American College of Medical Genet-
ics and Genomics (ACMG).12 Variant genes were 
described as newly identified (novel), candidate, 
or known to cause disease.2 Genes that were 
described as newly identified had not been im-
plicated in human disease previously and har-
bored distinct damaging variants in at least two 
affected patients with striking phenotypic over-
lap from unrelated families. When such a vari-
ant was observed in only a single family, it was 
described as a candidate gene.
R esult s
Patients
From October 2012 through January 2015, we 
recruited and completed whole-exome sequenc-
ing on samples obtained from 47 probands who 
met the eligibility criteria. All the patients were 
referred by local medical specialists in Vancou-
ver, Canada, except for 3 patients, who were re-
ferred by clinicians in Greece, the United King-
dom, and Saudi Arabia. Negative results on 
whole-exome sequencing that ruled out a mono-
genic cause and details regarding the clinical 
course at the time of the study helped to con-
firm previously suspected diagnoses of terato-
gen exposure (in 1 patient), congenital infection 
(in 1 patient), and an autoimmune disorder (in 
2 patients). In one patient, a chromosomal copy-
number variant that was classified as having un-
known significance before the study was deter-
mined to be pathogenic on the basis of a new 
entry in the ClinVar database (www . ncbi . nlm . nih 
. gov/ clinvar/ ), which describes the same copy-
number variant in an unrelated person with a 
similar phenotype. None of the remaining pa-
tients were identified as having a copy-number 
variant (either pathogenic or of unknown signifi-
cance). In addition, one family, for whom whole-
exome sequencing identified a de novo pathogenic 
variant in a known syndromic gene associated 
with intellectual developmental disorder, with-
drew from the study.
Of the 41 remaining probands, 37 (90%) were 
children. The age at the time of enrollment 
ranged from 8 months to 31 years (median, 5.9 
years); 15 of the probands were female (37%), 
and 26 were male (63%). Among these patients 
with intellectual developmental disorder, 19 had 
mild disease, 14 had moderate disease, and 8 had 
profound disease, with a spectrum of additional 
clinical and biochemical manifestations (Table 1). 
A total of 26 of the probands (63%) were of 
European descent and had been born to non-
consanguineous parents without a family history 
of intellectual developmental disorder. In all the 
probands, diagnostic investigations for intellec-
tual developmental disorder had been initiated 
during early childhood (in the 1990s through 
2014) with regular follow-up for additional test-
ing. All the patients had undergone biochemical 
testing according to a published diagnostic algo-
rithm for treatable intellectual developmental 
disorder10 and a combination of clinical genetics 
testing (including mitochondrial DNA sequenc-
ing) without receiving a diagnosis. Nine pro-
bands had affected siblings who also underwent 
whole-exome sequencing analyses. A summary 
of the results for all 50 patients (41 probands 
and 9 siblings) is provided in Table S1 in the 
Supplementary Appendix.
Diagnostic Yield
We established a genetic diagnosis in 28 of the 
41 probands (68%), which included the identifi-
cation of variants in 2 genes newly implicated in 
disease, 22 known genes with newly identified 
phenotypes, and 9 genes with expected pheno-
types. In most of the genes, the variants were 
classified as either pathogenic or probably patho-
genic. In 9 additional probands, we identified 
9 candidate genes (Table 2). Our group generat-
ed experimental data providing evidence for the 
effect of variants on protein function for 14 of 
these genes (2 newly implicated genes, 6 candi-
date genes, and 6 known genes with newly iden-
tified phenotypes) (Section C in the Supplemen-
tary Appendix).
We performed whole-exome sequencing on 
samples obtained from the proband and from 
both parents in 28 of the cases (68%). In total, 
we identified 58 diagnostic variants in 42 genes; 
all except the previously reported somatic KRAS 
variant were germ-line variants.13,14 Of the 58 vari-
ants, 24 (41%) were classified as pathogenic and 
17 (29%) as probably pathogenic, according to 
recently published ACMG standards and guide-
lines (Table S2 in the Supplementary Appen-
dix).12 Most of these variants (78%) were not 
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present in either our database (which consists of 
350 individual exomes or genomes) or the data-
base of single-nucleotide polymorphisms of the 
National Center for Biotechnology Information 
(dbSNP, version 138), whereas 13 variants were 
present but rare (average allele frequency, 0.006) 
in the dbSNP. Seven diagnostic variants (12%) 
had been previously identified as pathogenic 
(Table S3 in the Supplementary Appendix), a 
prevalence that is similar to that in a previous 
study.15 As compared with variants in the Exome 
Aggregation Consortium (ExAC), a database of 
61,486 unrelated persons, 31 of the 58 variants 
(53%) were newly identified and 27 (47%) were 
rare, with an average allele frequency of 0.004. 
The ExAC data set includes patients with mental 
illnesses, so the presence of a rare variant in this 
data set does not exclude the possibility that it is 
pathogenic.
Of the 58 variants, 51 (88%) were single-
nucleotide variants; these included 43 missense 
variants (74%), 4 nonsense variants (7%), and 
4 splice-site variants (7%); 4 in-frame omissions 
of conserved amino acids (7%) and 3 frameshift 
variants (5%) were also identified (Table 2). The 
mode of inheritance was recessive in 30 of the 
42 genes (71%), including compound heterozy-
gous variants in 16 genes (38%), homozygous 
variants in 8 genes (19%), and X-linked recessive 
variants in 6 genes (14%) (Table 3). Dominant 
variants were identified in 12 patients (29%), 
including 11 de novo variants (10 heterozygous 
and 1 mosaic) and a single familial autosomal 
dominant variant with variable penetrance. For 
the nine families with pathogenic variants in 
known human disease genes and expected phe-
notypes, pedigrees with electropherograms are 
provided in Figure S1 in the Supplementary Ap-
pendix.
Effect on Clinical Management
Genetic diagnosis affected the clinical treatment 
of 18 probands (44%) in whom a pathogenic 
or probably pathogenic variant was identified 
(Table S4 in the Supplementary Appendix). These 
changes consisted of preventive measures, such 
as regular screening for cancer and avoidance of 
disease triggers in 4 probands (with a variant in 
CBL,16 SMAD4, MTO1, or PRSS1); immune-modu-
lating therapies, such as chemotherapy or stem-
cell transplantation in 3 probands (with a vari-
Characteristic Proband
no. (%)
Sex
Male 26 (63)
Female 15 (37)
Age
<19 yr 37 (90)
≥19 yr 4 (10)
Family structure
Nonconsanguineous
One affected child 30 (73)
Two affected children 7 (17)
Consanguineous
One affected child 2 (5)
Two affected children 2 (5)
Population†
White European 26 (63)
East Asian 3 (7)
West Asian 7 (17)
South Asian 3 (7)
Latino 2 (5)
Phenotype
Intellectual developmental disorder 41 (100)
Unexplained metabolic phenotype 39 (95)
Abnormal neuroimaging 26 (63)
Abnormal muscle tone 18 (44)
Seizure 13 (32)
Abnormal movement 11 (27)
Epilepsy 11 (27)
Psychiatric symptoms 8 (20)
Dysmorphic features 8 (20)
Cardiac defect 7 (17)
Short stature 4 (10)
Immune dysfunction 4 (10)
Clinical, genetic, and biochemical analyses
Chromosomal microarray analysis 36 (88)
Targeted gene sequencing 34 (83)
Mitochondrial DNA sequencing 18 (44)
Biochemical testing 41 (100)
*  Percentages may not total 100 because of rounding.
†  The population group was determined by self-report and a detailed family 
 history.
Table 1. Clinical Characteristics of the 41 Probands.*
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ant in SENP1, SYTL2, or KRAS); more precise 
symptomatic treatment, such as supplementa-
tion with 5-hydroxytryptophan, levodopa, carbi-
dopa, serine, or folinic acid supplementation in 
5 probands (with a variant in CNKSR2, SCN2A, 
ANO3, ATP2B3, or MECP2); and treatments target-
ing the identified abnormality at a cellular or 
molecular level in 7 probands (with a variant in 
CA5A, ACACB, GOT2, PCK1, NANS, MTO1, or QARS). 
The diagnosis of MTO1 deficiency in a female 
sibling pair enabled both preventive and target-
ed therapy. Although it is possible that these 
changes in clinical treatment may have improved 
health outcomes in all cases, it must also be 
acknowledged that different degrees of stabiliza-
tion or improvement in patients with intellectual 
developmental disorder (or related outcomes) can 
be expected in different groups.
Illustrative Cases
New and Candidate Causes of Intellectual 
Developmental Disorder and Therapy
We describe two newly identified forms of in-
born errors of metabolism that are potentially 
amenable to dietary restriction, supplementation, 
or pharmacologic interventions (see Case Reports 
and Table S4 in the Supplementary Appendix). 
The first discovery was a homozygous missense 
variant in CA5A (Mendelian Inheritance in Man 
[MIM] number 114761), encoding mitochondrial 
carbonic anhydrase VA, which is pivotal to the 
function of mitochondrial enzymes.17 Our group 
reported that a deficiency in this enzyme causes 
neonatal hyperammonemia, hyperlactatemia, and 
hypoglycemia.17 Such a deficiency is amenable to 
treatment with carglumic acid and an emergency 
protocol, which can prevent irreversible neuro-
logic sequelae. We added this condition to the 
two-tiered diagnostic algorithm and interactive 
tool at Treatable ID.org (freely available as native 
and Web applications at www.treatable-id.org) 
to support clinicians in early identification.9,10
The second newly identified inborn error of 
metabolism was caused by compound heterozy-
gous variants in NANS, encoding N-acetylneur-
aminic acid phosphate synthase (MIM number 
605202), in a 4-year-old presenting with epileptic 
encephalopathy and dysmorphic features. We de-
tected increased levels of N-acetylated manno sa-
mine, the substrate of NANS, in his urine, 
plasma, and cerebrospinal fluid. Other recessive 
NANS variants have been identified in a cohort of 
eight other patients with similar phenotypes in 
five unrelated families. Models of the mutated 
organisms recapitulated the phenotype, which is 
amenable to treatment with early supplementa-
tion of N-acetylneuraminic acid.
In addition, we identified two candidate genes 
that led us to conclude that the phenotypes for 
Variable Value
Diagnosis by means of whole-exome sequencing — 
no. of probands
Positive diagnosis (single contributing gene) 32
Positive diagnosis (two contributing genes) 5
No diagnosis 4
Extent of whole-exome sequencing — no. of probands
Proband only 3
Proband and affected sibling 1
Proband and unaffected parent 1
Proband and both unaffected parents 28
Proband, affected sibling, and unaffected parents 5
Proband, unaffected sibling, and unaffected 
parents
3
Gene category — no. of genes (gene name)
Not previously implicated in human disease* 11
Newly identified gene 2 (NANS, CA5A)
Candidate gene 9 (ACACB, RBSN, GOT2, 
FAAH2, SENP1, 
SYTL2, RYR3, MFNG, 
NPL)
Known gene with a new phenotype 22
Known gene with a known phenotype 9
Type of variant — no.
All variants 58
Single-nucleotide variant 51
Missense 43
Nonsense 4
Splice-site 4
Insertion or deletion 7
In-frame 4
Frameshift 3
*  The classification by de Ligt et al.2 was used for genes that had not been im-
plicated in human disease previously. Genes were described as newly identi-
fied (novel) if additional unrelated families with striking phenotypic overlap 
and variants affecting the same gene were identified. Otherwise, a candidate 
classification was used.
Table 2. Diagnostic Yield and Summary of Whole-Exome Sequencing Analysis 
in 41 Probands.
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intellectual developmental disorder were poten-
tially treatable. In a 6-year-old boy with acquired 
microcephaly, severe seizure disorder, spasticity, 
sleep disturbances, abdominal spasms, and low 
levels of serine in plasma and cerebrospinal 
f luid, we identified compound heterozygous 
variants in GOT2 (MIM number 138150), encod-
ing mitochondrial glutamate oxaloacetate trans-
aminase.18 After receiving oral serine and pyri-
doxine supplements, the patient showed improved 
head growth, psychomotor development, and sei-
zure control. Finally, we are evaluating whether 
a deficiency in acetyl-coenzyme A carboxylase 
beta associated with compound heterozygous 
variants in ACACB (MIM number 601557) is a 
potentially treatable inborn error of metabolism.
Expansion of the Phenotypic Spectrum
We identified variants in 22 genes that have 
previously been reported to cause monogenic 
conditions19-25 (Table S4 in the Supplementary 
Appendix). In all these conditions, we observed 
previously unreported clinical symptoms.
The delineation of phenotype can point to 
new treatment targets. An example from this 
study was an 8-year-old boy with intellectual 
developmental disorder, autism, movement dis-
order, intractable epileptic encephalopathy, and 
persistently abnormal neurotransmitter profiles 
(low levels of homovanillic acid, 5-hydroxyindole-
acetic acid, and neopterin in cerebrospinal fluid) 
in whom we identified a de novo pathogenic 
splice-site variant. This mutation resulted in the 
deletion of exon 14 in SCN2A,24 encoding voltage-
gated sodium channel type II. Voltage-gated so-
dium channels are heteromeric complexes that 
generate and propagate action potentials. The 
known phenotype of SCN2A deficiency varies 
and includes benign forms of epilepsy, severe 
epileptic encephalopathy, autism, and intellectual 
developmental disorder without seizures, as well 
as rare cases of dystonia, hypotonia, and hyper-
somnia.26 Neurotransmitter deficiencies have not 
been described in this disorder previously. We 
hypothesized that this channelopathy causes ab-
normal synaptic secretion and uptake of mono-
amine metabolites through impaired vesicular 
release and imbalance in electrochemical ion 
gradients, which in turn aggravate the seizures. 
Treatment with oral 5-hydroxytryptophan, levo-
dopa, carbidopa, and a dopa agonist normalized 
the child’s levels of neurotransmitters in the 
cerebrospinal fluid and was associated with im-
provements in attention, communication, and 
seizure control.
Combined Phenotypes from Two Coexisting 
Monogenic Defects
Multiple genetic events leading to complex pheno-
types may be mistaken for new disorders or new-
ly identified phenotypes of a known disorder. 
This reminds us that a layer of unbiased and 
Inheritance
No. of Genes  
Affected Gene ID
Autosomal recessive
Compound heterozygous 16 ACACB, RMND1, QARS, MTO1, RYR3, H6PD, MFNG, SCN4A, 
NDST1, ANO3, NPL, NANS, TMEM67, SYTL2, GOT2, 
MAT1A
Homozygous 8 CA5A, RBSN, AIMP1, GALC, GJB2, PCK1, SENP1, OSMR
X-linked
Recessive 6 CNKSR2, PIGA, FAAH2, MED12, PLP1, ATP2B3
Dominant de novo heterozygous 1 MECP2
Autosomal dominant
De novo heterozygous 9 SCN2A, CBL, DYRK1A, SMAD4, KMT2A, KCNQ2, EHMT1, 
PACS1, PUF60
De novo mosaic 1 KRAS
Inherited 1 PRSS1
Table 3. Inheritance Patterns of the 42 Genes Identified in the Study.
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systematic interpretation of data from next-
generation sequencing is necessary in any clinical 
pipeline. Recent reports regarding next-genera-
tion sequencing support the hypothesis that 
blended phenotypes are an appreciable cause of 
disease.1,27 This concept was shown in our study 
group, in which 5 of 37 probands (14%) for 
whom diagnoses had been established harbored 
variants at two distinct disease loci associated 
with the phenotype (Table S5 in the Supplemen-
tary Appendix). For instance, in a 19-year-old 
male patient who was born to nonconsanguine-
ous Filipino parents and who had progressive 
dilated cardiomyopathy, sensorineural hearing 
loss, and unexplained sialic aciduria, whole-
exome sequencing revealed compound heterozy-
gous damaging missense variants in NPL (MIM 
number 611412) encoding N-acetylneuraminate 
pyruvate lyase (which controls the final step of 
sialic acid metabolism) and a known homozy-
gous missense variant in GJB2 (connexin 26) re-
ported to cause deafness.
Medically Actionable Incidental Findings
In the families of the 41 probands, we identified 
only one medically actionable incidental finding 
in CFTR (MIM number 602421). Both alleles 
(rs78655421 and rs121908745) had been previ-
ously reported to be pathogenic. These alleles 
were found to be in trans on Sanger sequencing. 
The clinical phenotype did not include symp-
toms of cystic fibrosis. The family chose not to 
be informed of incidental findings, so we did 
not disclose this result to them.
Discussion
Our approach, which involved phenotyping and 
whole-exome sequencing of samples obtained 
from 41 consecutively enrolled probands with 
intellectual developmental disorder who had an 
unexplained metabolic phenotype, provided a 
diagnostic yield of 68%, including variants in 
two newly implicated genes. We also identified 
nine candidate genes. Although the study was 
designed to evaluate the numerical yield of 
whole-exome sequencing in probands, affected 
siblings also benefited from a diagnosis in nine 
families (Table S1 in the Supplementary Appen-
dix). Studies to validate or rule out causality of 
the candidate genes are ongoing. We have pro-
vided information on variants that were possibly 
pathogenic in these genes using more stringent 
weighting of available genetic evidence according 
to ACMG guidelines12 and taking into account 
existing experimental data (Tables S2 and S4 and 
the Experimental Data section in the Supple-
mentary Appendix). Our diagnostic rate exceeds 
that of most published studies applying next-
generation sequencing in rare diseases.2,3,15,28-31
In one of four families with negative results 
on whole-exome sequencing, subsequent whole-
genome sequencing identified a causal homozy-
gous variant in CSTB (in a region of low coverage 
on whole-exome sequencing) in two siblings with 
neurodegenerative epilepsy who had a response 
to carbidopa–levodopa and 5-hydroxytryptophan. 
In another family, whole-exome sequencing of 
samples obtained from parents established a 
pathogenic de novo mutation (MYLK); previously, 
only the proband had undergone whole-exome 
sequencing analysis (see the Discussion section 
in the Supplementary Appendix). However, the 
most important outcome of our genomics study 
was the effect of diagnosis by means of whole-
exome sequencing on the clinical treatment of 
44% of the probands who were analyzed.
Knowledge of the precise genetic or biochem-
ical defect in a metabolic pathway provides the 
opportunity to modify disease by means of nu-
tritional manipulation, which does not require 
the expensive and time-consuming preclinical 
development that is typical in drug manufactur-
ing. This advantage is illustrated by the discov-
ery of GOT2 deficiency in a child with severe 
neurologic symptoms that was amenable to oral 
serine and pyridoxine supplements (the product 
and cofactor, respectively, of GOT2), both of 
which are affordable and have been deemed to 
be safe for other inborn errors of metabolism.9,32 
However, the diagnosis of NANS deficiency in 
another patient underscores a challenge pre-
sented by very rare diseases: how to test new 
treatments and obtain evidence of effect or lack 
thereof with a small number of patients.
The relatively high diagnostic yield that we 
report here may stem from the inclusion crite-
rion of a metabolic abnormality, the prevalence 
of recessive conditions in metabolic disorders, 
or the close consultation with clinical specialists 
in our bioinformatics pipeline. We observed a 
higher portion of patients (14%) with variants at 
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two distinct disease loci (leading to blended 
phenotypes) than has been observed in other 
studies,1,27 perhaps because we specified the in-
clusion of two phenotypes (metabolic and intel-
lectual developmental disorder) in the patient-
selection criteria.
Translational genomics requires collabora-
tions among patients, their families, subspecial-
ist clinicians for careful phenotyping, bioinfor-
maticians for accurate data analysis, and basic 
scientists engaged in specific research involving 
genes, pathways, or model organisms.33 Difficult 
decisions with respect to invasive and costly pro-
cedures such as hematopoietic stem-cell trans-
plantation or chemotherapy (e.g., in a patient 
with SYTL2 deficiency34) are facilitated and sup-
ported by a genetic diagnosis. Outcome reports 
of such cases in the literature may help to guide 
other clinicians who are facing similar deci-
sions. Data sharing and open communication 
are key to maximizing the diagnostic potential 
of next-generation sequencing and its clinical 
benefit in rare diseases.
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